Highlights Guilin Sanjin Pharmaceutical Co., Ltd.

Equities

002275

CNE100000DY9

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 15/05/2024 am IST			5-day change	1st Jan Change
14.86 ^CNY	-0.87%		+0.07%	+2.55%

25/04	Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04/03	Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Guilin Sanjin Pharmaceutical Co., Ltd. Proposes Final Dividend for 2023	27/04	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04/03	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Implements Profit Distribution plan for the Third Quarter of 2023, Payable on 27 November 2023	22/11	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves 2023 Third Quarter Profit Distribution Plan	16/11	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Proposes Third Quarter Dividend for 2023	31/23/31	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	29/23/29	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	24/23/24	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on May 31, 2023	25/23/25	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves Cash Dividend for 2022	23/23/23	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/23/27	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	27/23/27	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves Dividend for the Third Quarter of 2022	16/22/16	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Announces the Profit Distribution Proposal for the Third Quarter of 2022	01/22/01	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	28/22/28	CI
Biocytogen Pharmaceuticals Raises $60 Million in RemeGen-Backed Hong Kong IPO	31/22/31	MT
Biocytogen Pharmaceuticals Launches $70 Million Hong Kong IPO	19/22/19	MT
Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	18/22/18	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021, Payable on 30 May 2022	25/22/25	CI
Guilin Sanjin Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021	20/22/20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Guilin Sanjin Pharmaceutical Co., Ltd.

Equities

002275

CNE100000DY9

Highlights

Filters